Aldeyra Therapeutics (ALDX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 3[1].
Trial NCT07402876[3] evaluates ICM ADX-2191 injection in Primary Vitreoretinal Lymphoma with a target enrollment of 20 participants.
ALDX has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].